Announcements Trials
Browse Landscape

Phase

Phase NA 14Phase 1 3Phase 2 2Phase 4 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 150INDUSTRY 125NIH 14NETWORK 7FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Distress Syndrome 1Pneumonia 1Ovarian Neoplasms 1Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × FED × Lung Neoplasms × Clear all
NCT05467748 2026-01-27

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

VA Office of Research and Development

Phase 1/2 Recruiting
66 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡